Datopotamab deruxtecan plus Imfinzi demonstrated robust and durable tumour responses in BEGONIA Phase 1b/2 trial.
Updated results from the BEGONIA Phase Ib/II trial for the cohort of patients treated with datopotamab deruxtecan (Dato-DXd) plus Imfinzi (durvalumab) (Arm 7) showed that the combination demonstrated durable tumour responses and no new safety signals in patients with previously…